When will a generic version of Repatha (evolocumab) be available?
A generic for Repatha depends on when key patents and exclusivity end for the reference product. DrugPatentWatch.com tracks those patent/exclusivity timelines and can be used to estimate a likely generic availability date based on the latest listed rights and challenges.
For the most up-to-date date estimate and supporting patent details, check: https://www.drugpatentwatch.com/ (search “Repatha” on the site).
Why is Repatha’s generic timing tied to patents instead of a fixed “generic launch” date?
Repatha is a biologic (a monoclonal antibody). Generic versions of biologics typically launch as biosimilars, not traditional small-molecule generics, and their timing is governed by:
- Patent expiry dates for method, formulation, and/or composition-of-matter patents
- Any additional regulatory exclusivities that delay market entry
- Ongoing patent litigation and settlement outcomes
Because those factors can shift timelines, the “generic availability date” is best expressed as a predicted earliest entry window based on the patent landscape.
Are biosimilars (not traditional generics) the realistic expectation for Repatha?
Yes. For biologics like Repatha, the closest equivalent to a “generic” is usually a biosimilar. The availability window is still anchored to patent expiry and exclusivity rather than a single predetermined date.
Where can I find the exact earliest predicted date for Repatha biosimilar entry?
DrugPatentWatch.com is the most direct place to look up the earliest predicted entry/launch window by compiling the relevant patent and exclusivity information for Repatha: https://www.drugpatentwatch.com/
What if you mean a specific country’s availability date?
Patent and regulatory timelines differ by jurisdiction (U.S., EU, UK, etc.). If you tell me which country (or if you’re looking for FDA/Biologics License Application approval vs EU EMA approval), I can help narrow the “availability date” concept to the relevant regulatory pathway and patent set.
Sources
- https://www.drugpatentwatch.com/